Human variability in polymorphic CYP2D6 metabolism: Implications for the risk assessment of chemicals in food and emerging designer drugs
Authors:
Open Access
- 1 November 2021
- journal article
- research article
- Published by Elsevier in Environment International
- Vol. 156, 106760
Abstract
No abstract availableKeywords
Funding Information
- European Food Safety Authority (GP/EFSA/SCER/2015/01, OC/EFSA/SCER/2014/06)
This publication has 87 references indexed in Scilit:
- The weight of nations: an estimation of adult human biomassBMC Public Health, 2012
- Genetic Polymorphism and Toxicology—With Emphasis on Cytochrome P450Toxicological Sciences, 2010
- Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safetyBritish Journal of Pharmacology, 2010
- Toward Optimal Treatment in Women: The Effect of Sex on Metoprolol‐Diphenhydramine InteractionThe Journal of Clinical Pharmacology, 2010
- Polymorphism of Human Cytochrome P450 2D6 and Its Clinical SignificanceClinical Pharmacokinetics, 2009
- Atomoxetine pharmacokinetics in healthy Chinese subjects and effect of the CYP2D6*10 alleleBritish Journal of Clinical Pharmacology, 2007
- Apnea in a child after oral codeine: a genetic variant – an ultra‐rapid metabolizerPediatric Anesthesia, 2007
- Reboxetine and cytochrome P450 – comparison with paroxetine treatment in humansInt. Journal of Clinical Pharmacology and Therapeutics, 2007
- Use of toxicokinetic and toxicodynamic data to reduce uncertainties when setting occupational exposure limits for pharmaceuticalsHuman and Ecological Risk Assessment: An International Journal, 1997
- The concept of the acceptable daily intake: An historical review∗Food Additives & Contaminants, 1991